Antisense Oligonucleotides (ASOs)

Conference speaker
#Antibody #Antisense Oligonucleotides (ASOs) #Duchenne muscular dystrophy #Sapreme Therapeutics

Sapreme shares “unprecedented” preclinical data for Duchenne candidate

Sapreme Therapeutics has shared new preclinical data from its lead Duchenne muscular dystrophy (DMD) programme, SPM-2551, at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), taking place in Denver, Colorado, US.  SPM-2551 is intended to restore dystrophin to more than 15% of normal levels –… Read More

#News

#Antisense Oligonucleotides (ASOs) #Orphan drugs #Phase III trial #Rare disease #Ultragenyx

Ultragenyx’s ASO for Angelman Syndrome fails at Phase III

Ultragenyx Pharmaceutical has revealed that its Phase III Aspire study for apazunersen (GTX-102) in Angelman syndrome did not achieve its primary endpoint of change from Baseline in Bayley-4 cognitive raw score.  The trial also failed to achieve the key secondary endpoint of net response in Multidomain Responder… Read More

#News

#Antisense Oligonucleotides (ASOs) #CAMP4 Therapeutics #Collaboration #GSK #Kidney disease #Neurodegenerative disorders

CAMP4 and GSK advance RNA-based therapeutic discoveries

GSK and CAMP4 Therapeutics have entered into a strategic research, collaboration and license agreement to identify and develop antisense oligonucleotide (ASO) drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications.  “Protein under-expression plays a critical role in diseases such as neurodegenerative and kidney disease. Our collaboration… Read More

#Business & Investment #News

#Antisense Oligonucleotides (ASOs) #Artificial intelligence (AI) #Genetics / genomics #RNA

Advances in RNA therapeutics with CAMP4

DDW Editor Reece Armstrong speaks to Josh Mandel-Brehm, CEO of CAMP4 Therapeutics, about challenges in the discovery and development of RNA therapeutics. RA: Why has regulatory RNA historically not been exploited as a therapeutic target?  JMB: Historically, RNA has been viewed primarily as a messenger — a passive intermediary between… Read More

#Exclusive Content

Demyelination of neuron
#Antisense Oligonucleotides (ASOs) #Biotechnology #Rare disease #SynaptixBio

Biotech selects ASO drug candidate for incurable rare disease

Oxford-based SynaptixBio, which is developing a therapy for a rare, deadly, and currently incurable rare disease (H-ABC), says it has identified the drug it will take forward into clinical trials.  The drug, SB H-19642, is an antisense oligonucleotide (ASO), which is a short strand of synthetic DNA… Read More

#News

#Antisense Oligonucleotides (ASOs) #Gene silencing #Rare diseases

A rare opportunity for ASOs

Dan Williams, CEO of SynaptixBio, explains the science behind antisense oligonucleotides (ASOs) and the challenges and opportunities in using them to tackle rare diseases such as H-ABC. Gene silencing’ is a term used to describe the process of stopping a specific gene from making its associated protein. It is different… Read More

#Exclusive Content

#Antisense Oligonucleotides (ASOs) #Gene expression #Genetics / genomics #RNA

Antisense oligonucleotides: Navigating ethical and safety challenges

Tina Rogers, Senior Technical Director, Toxicology at WuXi AppTec, discusses the ethical and safety challenges of developing antisense oligonucleotides. Antisense oligonucleotides (ASOs) have emerged as a promising class of therapeutics, offering unique mechanisms to target and silence disease-causing genes. Unlike traditional small molecules or biologics, ASOs work by binding to… Read More

#Exclusive Content

#Antisense Oligonucleotides (ASOs) #Collaboration #Evotec #Partnership #Rare disease #SynaptixBio

SynaptixBio and Evotec extend rare disease therapies partnership

SynaptixBio and Evotec have announced they are extending their partnership to find further candidate drugs to treat H-ABC, the most severe form of TUBB4A leukodystrophy. The drug research was originally carried out by the Children’s Hospital of Philadelphia (CHOP), the world’s leading centre for leukodystrophy research,… Read More

#News

RNA strand
#Antisense Oligonucleotides (ASOs) #CAMP4 Therapeutics #CNS #Genetic diseases #mRNA #RNA #Turning Science into Business

Turning science into business: Amplifying mRNA by targeting regRNAs

DDW’s Diana Spencer speaks to Josh Mandel-Brehm, CEO of Massachusetts-based biotech CAMP4, to understand the role regulatory RNAs play in gene expression and how the founders overcame the challenge of launching a business based on brand new science. DS: CAMP4 leverages research from co-founder Richard Young on how regulatory RNA… Read More

#Business & Investment #Exclusive Content

A strip of 8 PCR tubes on the thermal cycler
#Antisense Oligonucleotides (ASOs) #CAMP4 Therapeutics #Gene mutation #Phase I trial #Rare disease

Potential first-in-class therapeutic for urea cycle disorders enters trial

CAMP4 Therapeutics has dosed the first participant in its Phase I clinical study of CMP-CPS-001, a potential first-in-class therapeutic for the treatment of urea cycle disorders (UCDs). UCDs are a group of rare, severe, inherited metabolic diseases impacting protein metabolism. Mutations in genes encoding urea cycle… Read More

#News

Demyelination of neuron
#Antisense Oligonucleotides (ASOs) #FDA #Orphan drugs #Rare disease #SynaptixBio

FDA Orphan Drug Designation awarded to rare disease therapies

UK-based biotech SynaptixBio has secured a second Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA). The company received its first ODD in early 2023 for a therapeutic that targets Hypomyelination with Atrophy of the Basal ganglia and Cerebellum (H-ABC), the most severe form of TUBB4A leukodystrophy. Read More

#News #Regulatory

Genetic engineering RNA
#Antisense Oligonucleotides (ASOs) #circular RNAs #Immunology / Virology & Vaccines #mRNA #RNA sequencing #siRNA

World RNA Day: What impact has RNA had on drug discovery?  

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Since then, it has been observed to publicise the importance of this molecule in the… Read More

#Exclusive Content